New hope for rare fat disorder: drug switch trial underway
NCT ID NCT06548100
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 29 times
Summary
This study tests a new experimental drug, mibavademab, in people with generalized lipodystrophy (GLD), a rare condition where the body can't store fat properly. Participants currently on the standard treatment metreleptin will switch to mibavademab to see if it is safe and tolerable. The study involves 9 adults and focuses on side effects and how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health
Bethesda, Maryland, 20892, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.